Pfizer today
As of 03:59 pm
- 52 weeks
- 20.92 dollars
▼
30.43 dollars
- Profit
- 7.24 %
- P/E ratio.
- 12.63
- The target price
- $ 28.12
In the US health care sector, a new growth issue shows that almost all companies want to benefit from them. Like artificial intelligence of technology stocks, the manufacturing and distribution of weight -loss drugs are all of the noise of the new growth wave that takes into account this industry.
However, there are two companies to take advantage of this opportunity and provide value to the shareholders.
The first is the development of special weight loss medications, but by the time it is set in organizational experiments, it may have been too late, because other companies in this industry have already achieved a penetration.
The second is by acquiring, although only the largest and strongest companies can pass this process. They can “bend” their financial muscles by combining their business with their smaller business and their full potential.
This is where the company likes 136.9 billion dollars Pfizer Inc. Nyse: pfe The headlines have been released, and the two options are chosen this time. A press release surprised investors when they learned that Pfizer is looking to close the value of the transaction Between 4.9 billion dollars and 7.3 billion dollarsAcquisition Cities Inc. Nasdak: MTSR.
This acquisition sent 57.6 % MetSera shares in one week. However, the real upward trend is likely to be achieved when it is integrated with Pfizer next time.
How is the Pfizer stock will be affected
First of all, Pfizer will now be exposed to the high -growth weight loss products market. MetSera injections with PFIZER and financial ingenuity increases the possibility of a successful product launch, which would expand Pfizer’s work beyond vaccines and traditional drug products, which reduces financial fluctuations.
More than just adding a new production line, the addition is mainly a “shoe” for Pfizer, as it already has a commercial infrastructure that works in average capacity. Therefore, the added task for manufacturing weight loss will be a small step in the needle in terms of additional costs.
In other words, this new section will carry the level of the margin higher than the average to complete it at PFIZER, which will be subject to the expansion of profits to the arrow (EPS) and the stock evaluation.
Although this may seem, Pfizer is still trading only 80 % of his highest level in 52 weeks, where investors can start interfering early.
The stock lock can be able to expose new shareholders to the positive effects that this new work can cause on PFIZER before it becomes clear to the rest of the market. On this subject of perception, there is one major catalyst that investors can now look forward to, which will come directly from Wall Street.
Where Phazer can go after that
Even without the collaboration in the potential benefits to acquire MetSera, the current Wall Street consensus target is determined at $ 28.12 per share, accompanied by a comment classification. This view still involves a clear net potential of 16.8 % of today’s prices, so that investors can start a starting point.
However, in the acquisition, Pfizer Management reported that it will update their financial instructions and expectations during the issuance of the fourth quarter profits. For retail investors, Wall Street analysts are now racing to be the first to lead their new goals on Pfizer before the announcement.
Given the upcoming future expectations to combine these two companies, these new classifications are expected to be much higher than consensus. Although this incentive in the future remains speculative (although the possibility of possibility), investors also have a few current indicators that can link points for this current development within the company.
Over the course of last month, the short interest of PFIZER decreased by 9.1 % although there is no bullish work. Perhaps the opinion was that, with the start of the weight loss market, Pfizer only needs a small boost towards a decision to make such a acquisition, which is enough of the idea to scare some sellers although there is no reason to do this in the same plan.
More than just saving sellers on the open, some institutional buyers were comfortably buying Pfizer before advertising.
One of them is Canada Life Assurance, which recently increased PFIZER’s shares of 19.6 % as of August 2025. While timing was a month of advertisement, accumulation cannot be ignored to a new position worth $ 207.7 million.
Whether dozens of analysts who are able to work in a company like Canada Life Assurance or not, but not, but what is not that there is enough institutional interest, even before the financial benefits of this acquisition become clear. Then there is a Boost Catalyst analyst that is still playing, waiting for investors to benefit from it.
Before you think about Pfizer, you will want to hear this.
Marketbeat follows the best research analyst at Wall Street, the best performance in Wall Street and the stocks they recommend to their customers on a daily basis. Marketbeat has selected the five shares whom the top analysts quietly whispered to their customers to buy now before hunting the broader market … PFIZER was not in the list.
While Pfizer is currently having a suspended classification among analysts, higher -rated analysts believe that these five stocks buy better.
Show the five stocks here
Nuclear energy shares roar. It is the most important energy sector for this year. Cameco Corp, Paladin Energy and BWX Technologies increased by more than 40 % in 2024. The largest market movements can remain in front of us, and there are seven nuclear energy shares that may rise in the next few months. To cancel these indicators, enter your email address below.
